Overview
Compare with ELITE PHARMACEUTICALS INC /NV/, Clovis Oncology or Karyopharm Therapeutics Inc., or pick any stock.
- TickerMGNX on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersRockville, United States2
- Incorporated inDE3
- Business address9704 Medical Center Drive, Rockville, Md 208503
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI5493001KJQUA83L8MH792
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 32740052
See how the biggest companies compare on our leaderboards
All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-48.7%Operating margin5
-49.9%Net margin5
-0.3%Revenue growth, 20255
-134.2%Return on equity5
-$83.0MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Revenue From Collaborative Agreements brought in 58% of the revenue MACROGENICS INC broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue From Collaborative Agreements | $30.5M | $119.9M | $87.2M |
| Contract Manufacturing | $9.8M | $13.1M | $52.6M |
| Revenue From Royality Agreements | $431.0K | $561.0K | $9.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development98¢$147.2M
- Other costs1¢$1.7M
- Income tax0¢$672.0K
Out of $149.5M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $149.5M | $150.0M | $58.7M |
| Cost of product sales | $0 | $847.0K | $619.0K |
| Cost of manufacturing services | $36.0M | $11.5M | $7.6M |
| Research and development | $147.2M | $177.2M | $166.6M |
| Selling, general and administrative | $39.2M | $71.0M | $52.2M |
| Total costs and expenses | $222.3M | $260.5M | $227.0M |
| Loss from operations | -$72.8M | -$110.6M | -$168.2M |
| Gain on royalty monetization arrangement | $0 | $0 | $150.9M |
| Gain on sale of MARGENZA | $0 | $36.2M | $0 |
| Interest and other income | $6.1M | $9.4M | $9.7M |
| Interest and other expense | -$8.5M | -$1.1M | -$1.4M |
| Loss before income taxes | -$75.3M | -$66.0M | -$9.1M |
| Income tax (benefit) expense | -$672.0K | $944.0K | $0 |
| Net loss | -$74.6M | -$67.0M | -$9.1M |
| Unrealized gain (loss) on investments | $28.0K | $10.0K | -$1.0K |
| Comprehensive loss | -$74.6M | -$67.0M | -$9.1M |
| Basic and diluted net loss per common share, basic (in dollars per share) | -$1.18 | -$1.07 | -$0.15 |
| Basic and diluted net loss per common share, diluted (in dollars per share) | -$1.18 | -$1.07 | -$0.15 |
| Basic weighted average number of common shares outstanding (in shares) | 63.2M shares | 62.6M shares | 61.9M shares |
| Diluted weighted average number of common shares outstanding (in shares) | 63.2M shares | 62.6M shares | 61.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $57.2M | $182.8M | ||
| Marketable securities | $132.7M | $18.8M | ||
| Accounts receivable | $13.4M | $4.3M | ||
| Inventory, net | $7.9M | $0 | ||
| Prepaid expenses and other current assets | $8.7M | $11.5M | ||
| Total current assets | $219.9M | $217.5M | ||
| Property, equipment and software, net | $12.6M | $18.1M | ||
| Operating lease right-of-use assets | $22.9M | $24.5M | ||
| Other non current assets | $1.4M | $1.6M | ||
| Total assets | $256.8M | $261.7M | ||
| Accounts payable | $4.8M | $5.0M | ||
| Accrued expenses and other current liabilities | $22.2M | $29.3M | ||
| Deferred revenue | $10.9M | $16.3M | ||
| Lease liabilities | $5.2M | $4.9M | ||
| Total current liabilities | $43.1M | $55.5M | ||
| Liability related to future royalties | $70.0M | $0 | ||
| Deferred revenue, net of current portion | $55.5M | $55.5M | ||
| Lease liabilities, net of current portion | $31.6M | $32.6M | ||
| Other non current liabilities | $1.1M | $2.0M | ||
| Total liabilities | $201.3M | $145.6M | ||
| Common stock, 0.01 par value -- 125,000,000 shares authorized, 63,318,613 and 62,819,857 shares outstanding at December 31, 2025 and December 31, 2024, respectively | $633.0K | $628.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive gain | $32.0K | $4.0K | ||
| Accumulated deficit | -$1.2B | -$1.2B | ||
| Total stockholders' equity | $55.6M | $116.1M | $152.6M | $142.0M |
| Total liabilities and stockholders' equity | $256.8M | $261.7M | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 125.0M shares | 125.0M shares | ||
| Common stock, shares outstanding (in shares) | 63.3M shares | 62.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $57.2M | $182.8M | ||
| Marketable securities | $132.7M | $18.8M | ||
| Accounts receivable | $13.4M | $4.3M | ||
| Inventory, net | $7.9M | $0 | ||
| Prepaid expenses and other current assets | $8.7M | $11.5M | ||
| Total current assets | $219.9M | $217.5M | ||
| Property, equipment and software, net | $12.6M | $18.1M | ||
| Operating lease right-of-use assets | $22.9M | $24.5M | ||
| Other non current assets | $1.4M | $1.6M | ||
| Total assets | $256.8M | $261.7M | ||
| Accounts payable | $4.8M | $5.0M | ||
| Accrued expenses and other current liabilities | $22.2M | $29.3M | ||
| Deferred revenue | $10.9M | $16.3M | ||
| Lease liabilities | $5.2M | $4.9M | ||
| Total current liabilities | $43.1M | $55.5M | ||
| Liability related to future royalties | $70.0M | $0 | ||
| Deferred revenue, net of current portion | $55.5M | $55.5M | ||
| Lease liabilities, net of current portion | $31.6M | $32.6M | ||
| Other non current liabilities | $1.1M | $2.0M | ||
| Total liabilities | $201.3M | $145.6M | ||
| Common stock, 0.01 par value -- 125,000,000 shares authorized, 63,318,613 and 62,819,857 shares outstanding at December 31, 2025 and December 31, 2024, respectively | $633.0K | $628.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive gain | $32.0K | $4.0K | ||
| Accumulated deficit | -$1.2B | -$1.2B | ||
| Total stockholders' equity | $55.6M | $116.1M | $152.6M | $142.0M |
| Total liabilities and stockholders' equity | $256.8M | $261.7M | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 125.0M shares | 125.0M shares | ||
| Common stock, shares outstanding (in shares) | 63.3M shares | 62.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$74.6M | -$67.0M | -$9.1M |
| Depreciation and amortization | $7.2M | $7.5M | $9.6M |
| Amortization of premiums and discounts on marketable securities | -$1.6M | -$2.8M | -$5.0M |
| Share-based compensation | $14.3M | $29.4M | $18.4M |
| Gain on royalty monetization arrangement | $0 | $0 | -$150.9M |
| Gain on sale of MARGENZA | $0 | -$36.2M | $0 |
| Non-cash royalty revenue | -$7.9M | $0 | $0 |
| Non-cash interest expense | $8.3M | $0 | $1.4M |
| Non-cash lease expense | $1.8M | -$663.0K | $3.5M |
| Other non-cash items | $0 | $2.0K | $423.0K |
| (Gain) loss on disposal of assets | -$10.0K | -$57.0K | $111.0K |
| Accounts receivable | -$9.1M | $6.1M | $45.9M |
| Inventory | -$7.9M | -$2.2M | $230.0K |
| Prepaid expenses and other current assets | $2.8M | -$1.6M | $215.0K |
| Other non current assets | $0 | -$170.0K | -$7.0K |
| Accounts payable | -$280.0K | -$1.5M | $1.3M |
| Accrued expenses and other current liabilities | -$6.8M | $5.0M | -$4.8M |
| Lease liabilities | -$699.0K | $3.5M | -$861.0K |
| Deferred revenue | -$5.4M | -$9.4M | $11.4M |
| Other non current liabilities | -$916.0K | $1.7M | $0 |
| Net cash used in operating activities | -$81.0M | -$68.4M | -$78.2M |
| Purchases of marketable securities | -$208.3M | -$77.2M | -$239.7M |
| Proceeds from sales and maturities of marketable securities | $96.1M | $190.0M | $161.3M |
| Purchases of property, equipment and software | -$1.9M | -$3.7M | -$1.8M |
| Proceeds from sale of MARGENZA | $0 | $40.0M | $0 |
| Proceeds from sales of equipment | $11.0K | $160.0K | $64.0K |
| Net cash provided by (used in) investing activities | -$114.1M | $149.3M | -$80.1M |
| Proceeds from issuance of common stock, net of offering costs | $0 | $0 | $616.0K |
| Proceeds from stock option exercises and ESPP purchases | $129.0K | $3.4M | $553.0K |
| Taxes paid related to net share settlement of equity awards | -$288.0K | -$2.5M | -$306.0K |
| Principal payments on royalty monetization arrangement | $0 | $0 | -$157.0K |
| Net proceeds from sale of future royalties | $69.7M | $0 | $149.7M |
| Net cash provided by financing activities | $69.5M | $960.0K | $150.4M |
| Net change in cash and cash equivalents | -$125.6M | $81.9M | -$7.9M |
| Property and equipment included in accounts payable or accruals | $54.0K | $100.0K | $505.0K |
No quarter-by-quarter statement was filed.
Corporate structure
MACROGENICS INC sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of MACROGENICS INC
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on MACROGENICS INC, latest Aug 14, 2026 (9 filings since Feb 14, 2023)
- Bank of America Filed SCHEDULE 13G/A on MACROGENICS INC, latest Aug 3, 2026 (2 filings since May 14, 2026)
- BlackRock Filed SCHEDULE 13G on MACROGENICS INC, latest Jul 29, 2026 (7 filings since Feb 3, 2022)
- MILLENNIUM MANAGEMENT LLC Filed SCHEDULE 13G/A on MACROGENICS INC, latest Jul 20, 2026 (8 filings since Sep 2, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on MACROGENICS INC, latest Mar 27, 2026 (4 filings since Feb 10, 2022)
- Frazier Life Sciences Public Fund, L.P. Filed SCHEDULE 13G/A on MACROGENICS INC, latest Feb 13, 2026 (3 filings since Nov 20, 2024)
- Bellevue Group Filed SCHEDULE 13G/A on MACROGENICS INC, latest Jan 6, 2026 (2 filings since Jul 7, 2025)
- WASATCH ADVISORS LP Filed SCHEDULE 13G/A on MACROGENICS INC, latest Nov 12, 2025 (4 filings since Feb 11, 2022)
- BB Biotech Filed SCHEDULE 13G/A on MACROGENICS INC, latest Jun 13, 2025 (5 filings since Feb 11, 2022)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on MACROGENICS INC, latest Feb 14, 2025 (5 filings since Feb 14, 2022)
- T. Rowe Price Investment Management, Inc. Filed SC 13G on MACROGENICS INC, latest Feb 14, 2024
- RTW INVESTMENTS, LP Filed SC 13G/A on MACROGENICS INC, latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- MACROGENICS INC Rockville, Maryland, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What MACROGENICS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Construction in progress | $371.0K5 Dec 31, 2025 | $1.2M5 Dec 31, 2024 | −69.5% |
| Property and equipment, before depreciation | $108.4M5 Dec 31, 2025 | $106.8M5 Dec 31, 2024 | +1.5% |
| Accumulated depreciation | $95.8M5 Dec 31, 2025 | $88.7M5 Dec 31, 2024 | +8.0% |
| Property and equipment, net | $12.6M5 Dec 31, 2025 | $18.1M5 Dec 31, 2024 | −30.2% |
| Operating-lease assets (leased space) | $22.9M5 Dec 31, 2025 | $24.5M5 Dec 31, 2024 | −6.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $57.2M5 Dec 31, 2025 | $182.8M5 Dec 31, 2024 | −68.7% |
| Debt securities available for sale | $132.7M5 Dec 31, 2025 | $18.8M5 Dec 31, 2024 | +604.8% |
Inventory
Properties, in its own words
We lease a total of approximately 190,000 square feet of manufacturing, office, laboratory and warehouse space in Maryland. Our headquarters building in Rockville, Maryland currently houses laboratory, office and manufacturing operations to support clinical and commercial quantities and scale. This location is occupied under a lease that expires in 2035. Our leases each have one or more five-year options to renew. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.
Item 2 of the 10-K filed Mar 9, 2026.4
Leadership
Who has led MACROGENICS INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerEric Blasius Risser Aug 15, 2025 to now13
- Chief executive officerScott Koenig Oct 9, 2013 to Aug 15, 202514
- PresidentEric Blasius Risser Aug 15, 2025 to now13
- PresidentScott Koenig Oct 9, 2013 to Aug 15, 202514
- Chief financial officerJames Karrels Oct 9, 2013 to now15
- Chief operating officerEric Blasius Risser Feb 24, 2022 to now16
Board members and other officers (27)
- Senior VP, GC, and SecretaryJeffrey Stuart Peters Feb 10, 2026 to now17
- Chief Medical OfficerStephen L. Eck Jul 6, 2020 to now18
- Vice President, DevelopmentThomas Spitznagel May 27, 2016 to now19
- OfficerAtul Saran Jun 9, 2014 to Oct 30, 201420
- V P, Business DevelopmentEric Blasius Risser Oct 9, 2013 to Feb 24, 202121
- Senior V P, ResearchEzio Bonvini Oct 9, 2013 to now22
- Senior V P, Clinical Dev.Jon Marc Wigginton Oct 9, 2013 to Feb 24, 202023
- Senior V P, Product Dev & Reg.Kathryn E. Stein Oct 9, 2013 to Jan 11, 201624
- V P, Controller and TreasurerLynn Cilinski Oct 9, 2013 to Feb 20, 202425
- V P, Clinical OncologyStanford John Stewart Oct 9, 2013 to Oct 11, 201326
- Board memberEric Blasius Risser Aug 15, 2025 to now13
- Board memberMargaret Liu Jan 5, 2023 to now27
- Board memberMeenu Chhabra Jan 5, 2023 to now28
- Board memberWilliam K. Heiden May 24, 2022 to now29
- Board memberFederica F. O'Brien Feb 12, 2021 to now30
- Board memberKaren Jean Ferrante Jan 25, 2017 to now31
- Board memberScott Thomas Jackson Jan 25, 2017 to now32
- Board memberJay Philip Siegel Nov 15, 2017 to now33
- Board memberArnold L. Oronsky Oct 9, 2013 to Feb 18, 201434
- Board memberDavid C. Stump Oct 9, 2013 to now35
- Board memberEdward Hurwitz Oct 9, 2013 to now36
- Board memberEran Nadav Oct 9, 2013 to Oct 11, 201337
- Board memberKenneth Galbraith Oct 9, 2013 to May 17, 202138
- Board memberPaulo F. Costa Oct 9, 2013 to May 17, 202139
- Board memberScott Koenig Oct 9, 2013 to now14
- General counselJeffrey Stuart Peters May 22, 2017 to now40
- General counselAtul Saran Dec 16, 2014 to May 2, 201741
Timeline
- Sep 3, 20268-K Financial statements and exhibits42
- Aug 13, 20268-K Results of operations43
- Jul 23, 20268-K Other events44
- Jul 8, 20268-K Executive or director change45
- Jul 7, 20268-K Completed an acquisition or sale; Regulation FD disclosure46
- May 20, 20268-K Shareholder vote47
- May 13, 20268-K Results of operations48
- May 12, 20268-K Entered a material agreement; Regulation FD disclosure49
- May 4, 20268-K Entered a material agreement; Other events50
- Apr 8, 20268-K Other events51
- Mar 9, 20268-K Results of operations52
- Mar 2, 20268-K Other events53
- Aug 15, 2025New chief executive Eric Blasius Risser becomes CEO13
- Oct 9, 2013New chief executive Scott Koenig becomes CEO14
- Aug 14, 2000Founded MACROGENICS INC is founded2
Calendar
Coming up
- Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.27 a share, on Nov 12, 2025.54
When it reported results
- Aug 13, 2026Reported quarterly or annual results43
- May 13, 2026Reported quarterly or annual results48
- Mar 9, 2026Reported quarterly or annual results52
- Nov 12, 2025Reported quarterly or annual results55
- Aug 14, 2025Reported quarterly or annual results56
- May 13, 2025Reported quarterly or annual results57
- Mar 20, 2025Reported quarterly or annual results58
- Nov 5, 2024Reported quarterly or annual results59
Drug trials and FDA: coming up
- Jul 2027Phase 2 trial readout expected Phase 2 trial of Lorigerlimab in Platinum-resistant Ovarian Cancer: primary completion expected Jul 2027 (ClinicalTrials.gov NCT06730347).60
Drug trials and FDA: recently
- Feb 19, 2026Phase 2 trial completed Phase 2 trial of lorigerlimab, docetaxel and others in Androgen-Independent Prostatic Cancer: primary completion Feb 19, 2026, no results posted yet (ClinicalTrials.gov NCT05848011).61
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
345 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 58 major events, 166 insider forms, 55 large holders, 46 other. The latest 20:
- Oct 7, 20264 EDGAR
- Sep 21, 2026144 EDGAR
- Sep 3, 2026S-8 EDGAR
- Sep 3, 20268-K/A EDGAR
- Aug 20, 20264 EDGAR
- Aug 19, 2026144 EDGAR
- Aug 18, 20264 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 13, 20268-K EDGAR
- Aug 3, 2026144 EDGAR
- Aug 3, 2026SCHEDULE 13G/A EDGAR
- Jul 29, 2026SCHEDULE 13G EDGAR
- Jul 23, 20268-K EDGAR
- Jul 20, 2026SCHEDULE 13G/A EDGAR
- Jul 13, 2026144 EDGAR
- Jul 8, 20268-K EDGAR
- Jul 7, 20268-K EDGAR
- Jun 5, 2026SCHEDULE 13G EDGAR
The 345 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
30 open-market trades by officers, directors and large owners since October 2021: 16 buys and 14 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Sale | 31,105 | $4.15 | $129.1K | Form 4 |
| Aug 20, 2025 | HEIDEN WILLIAM KDirector | Buy | 49,500 | $1.49 | $73.8K | Form 4 |
| Aug 19, 2025 | HEIDEN WILLIAM KDirector | Buy | 50,500 | $1.52 | $76.8K | Form 4 |
| Feb 15, 2025 | Smith Beth AnnVP, Controller & Treasurer | Sale | 423 | $2.56 | $1.1K | Form 4 |
| Apr 4, 2024 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Sale | 51,395 | $15.55 | $799.1K | Form 4 |
| Mar 6, 2024 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Sale | 19,625 | $21.50 | $421.9K | Form 4 |
| Mar 4, 2024 | Risser Eric BlasiusPresident and CEO | Sale | 41,159 | $19.76 | $813.5K | Form 4 |
| Mar 4, 2024 | Spitznagel ThomasSr VP, Technical Ops | Sale | 10,000 | $20.00 | $200.0K | Form 4 |
| Mar 4, 2024 | Karrels JamesSVP and CFO | Sale | 30,000 | $20.50 | $615.0K | Form 4 |
| Feb 26, 2024 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Sale | 16,124 | $17.22 | $277.7K | Form 4 |
| Feb 7, 2024 | Bonvini EzioSr VP, Research & CSO | Sale | 3,334 | $18.00 | $60.0K | Form 4 |
| Feb 5, 2024 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Sale | 76,251 | $16.50 | $1.3M | Form 4 |
| Feb 1, 2024 | Bonvini EzioSr VP, Research & CSO | Sale | 13,316 | $15.00 | $199.7K | Form 4 |
| Jan 19, 2024 | Bonvini EzioSr VP, Research & CSO | Sale | 13,316 | $12.00 | $159.8K | Form 4 |
| Dec 20, 2023 | Bonvini EzioSr VP, Research & CSO | Sale | 18,880 | $10.08 | $190.3K | Form 4 |
| Oct 2, 2023 | BB BIOTECH AG10% owner | Buy | 150,000 | $4.46 | $669.0K | Form 4 |
| Sep 7, 2023 | BIOTECH TARGET N V10% owner | Buy | 200,000 | $5.26 | $1.1M | Form 4 |
| Aug 30, 2023 | HURWITZ EDWARDDirector | Buy | 15,000 | $4.91 | $73.7K | Form 4 |
| Mar 10, 2023 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Sale | 5,372 | $6.03 | $32.4K | Form 4 |
| Feb 14, 2023 | BB BIOTECH AG10% owner | Buy | 500,000 | $5.07 | $2.5M | Form 4 |
All 30 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 9 filings Feb 14, 2023 to Aug 14, 202662
- Bank of AmericaSCHEDULE 13G/A, 2 filings May 14, 2026 to Aug 3, 202663
- BlackRockSCHEDULE 13G, 7 filings Feb 3, 2022 to Jul 29, 202664
- MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 8 filings Sep 2, 2022 to Jul 20, 202665
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 10, 2022 to Mar 27, 202666
- Frazier Life Sciences Public Fund, L.P.SCHEDULE 13G/A, 3 filings Nov 20, 2024 to Feb 13, 202667
- Bellevue GroupSCHEDULE 13G/A, 2 filings Jul 7, 2025 to Jan 6, 202668
- WASATCH ADVISORS LPSCHEDULE 13G/A, 4 filings Feb 11, 2022 to Nov 12, 202569
- BB BiotechSCHEDULE 13G/A, 5 filings Feb 11, 2022 to Jun 13, 202570
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 5 filings Feb 14, 2022 to Feb 14, 202571
- T. Rowe Price Investment Management, Inc.SC 13G, 1 filing Feb 14, 202472
- RTW INVESTMENTS, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202373
- Goldman SachsSC 13G/A, 2 filings Feb 4, 2022 to Feb 8, 202374
- InvescoSC 13G/A, 1 filing Jan 31, 202275
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Eric Risser | 53 | $561.6K | $2.1M76 |
| 2025 | Ezio Bonvini | 72 | $533.2K | $1.2M76 |
| 2025 | James Karrels | 59 | $506.5K | $1.1M76 |
| 2025 | Scott KoenigM.D., Ph.D. | $477.1K | $953.0K76 | |
| 2024 | Former ChiefExecutive Officer and current Director | $734.0K | $6.4M76 | |
| 2024 | Senior VicePresident and Chief Financial Officer | $491.1K | $2.4M76 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Armistice Capital, LLC | 5,006,752 | $23.1M | 0.6% | −1,005,248 |
| BlackRock, Inc. | 4,679,229 | $21.6M | 0.0% | +3,516,083 |
| Vanguard Capital Management LLC | 2,656,010 | $12.3M | 0.0% | +2,157 |
| Renaissance Technologies LLC | 2,632,750 | $12.2M | 0.0% | −330,809 |
| Bank Of America Corp /de/ | 2,488,252 | $11.5M | 0.0% | +86,438 |
| Two Sigma Investments, LP | 2,465,699 | $11.4M | 0.0% | −62,130 |
| Millennium Management LLC | 2,374,296 | $11.0M | 0.0% | −420,061 |
| Wasatch Advisors LP | 2,018,881 | $9.3M | 0.1% | +459,180 |
| Ra Capital Management, L.P. | 1,864,176 | $8.6M | 0.1% | No change |
| Vanguard Portfolio Management LLC | 1,820,231 | $8.4M | 0.0% | +611,456 |
| Mackenzie Financial Corp | 1,642,626 | $7.6M | 0.0% | +1,045,184 |
| Marshall Wace, Llp | 1,616,220 | $7.5M | 0.0% | −409,306 |
| Geode Capital Management, LLC | 1,576,549 | $7.3M | 0.0% | +879,228 |
| Affinity Asset Advisors, LLC | 1,216,606 | $5.6M | 0.3% | +716,606 |
| D. E. Shaw & Co., Inc. | 1,062,991 | $4.9M | 0.0% | +4,567 |
| Jacobs Levy Equity Management, Inc | 1,002,274 | $4.6M | 0.0% | +561,131 |
| Connor, Clark & Lunn Investment Management Ltd. | 1,000,412 | $4.6M | 0.0% | +133,163 |
| State Street Corp | 863,663 | $4.0M | 0.0% | +569,976 |
| Goldman Sachs Group Inc | 558,001 | $2.6M | 0.0% | +284,523 |
| Northern Trust Corp | 516,129 | $2.4M | 0.0% | +363,847 |
| Vanguard Fiduciary Trust Co | 420,106 | $1.9M | 0.0% | +80,017 |
| Nomura Asset Management International Inc. | 420,000 | $1.9M | 0.0% | No change |
| Walleye Capital LLC | 408,150 | $1.9M | 0.0% | +72,885 |
| Dimensional Fund Advisors LP | 379,335 | $1.8M | 0.0% | +127,532 |
| Diadema Partners LP | 374,403 | $1.7M | 0.7% | −225,597 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How MACROGENICS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARMACROGENICS INC1
- CIK0001125345
- Employer ID (EIN)06-15916134
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address9704 Medical Center Drive, Rockville, MD 208501
- Phone301-251-51721
- Shares outstanding63,700,187 as of Aug 8, 202611
- Public float$73.9M as of Jun 30, 20254
- AuditorErnst & Young LLP, Tysons, Virginia PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceNov 12, 20031
- Filings937 in all: 4 (433), 8-K (146), SC 13G/A (64), 10-Q (39), 3 (32), SC 13G (30), SCHEDULE 13G/A (18), 144 (16)1
All 38 form types
S-8 (15), 10-K (13), DEF 14A (13), UPLOAD (13), CORRESP (11), CT ORDER (11), DEFA14A (11), 424B5 (10), 4/A (9), 5 (6), EFFECT (6), S-1/A (6), SCHEDULE 13G (6), REGDEX (5), S-3 (3), 10-K/A (2), 424B4 (2), 8-K/A (2), ARS (2), S-1 (2), S-3ASR (2), 424B3 (1), 8-A12B (1), CERTNAS (1), D (1), DRS (1), POS AM (1), POSASR (1), PRE 14A (1), S-1MEF (1)
- Latest filingsAnnual report (10-K) Mar 9, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Apr 8, 2026
Latest 8-K (8-K) Aug 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.01 per share | MGNX | Nasdaq Global Select Market |
From the cover page of the 10-K filed Mar 9, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks MACROGENICS INC names in Item 1A of its 10-K filed Mar 9, 2026: 51 risks under these headings, as written.4
- Risks Related to Our Financial Position and Need for Additional Capital
- We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.
- We have incurred significant losses since inception and anticipate continuing to incur losses for the foreseeable future. We may never achieve or sustain profitability.
- Our business could be adversely affected by economic downturns, inflation, increases in interest rates, disruption in global supply chains, natural disasters, political crises, geopolitical events, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights.
- Our ability to use our net operating loss carryforwards and other tax attributes may be limited.
- Risks Related to Our Business and the Development and Commercialization of Our Product Candidates
- We depend substantially on the success of the clinical development of our product candidates, through our own efforts or those of our collaborators. If we or our collaborators are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed and we may not be able to generate sufficient revenues and cash flows to continue our operations.
- Drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of our product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other product candidates.
- If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.
- The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis,
- the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval.
The other 40 risks
- Certain of our antibody-drug conjugate, or ADC, product candidates incorporate technology developed by our collaboration partners. To date, no ADC product candidates incorporating any such technology have been approved by the FDA.
- We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- Our product candidates, if approved, may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- Our product candidates may have undesirable side effects, including fatalities. These side effects may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
- Our manufacturing facility is subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.
- Our manufacturing facility is not currently being primarily utilized for the production of our own product candidates, and we may not be able to efficiently and effectively offset the costs of maintaining the facility through contract manufacturing services for third parties in the future.
- We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product candidates or if they are ahead of us in development, our current or future commercial opportunities may be negatively impacted.
- The manufacture of products or product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of products or product candidates for ourselves or our collaborators, if and when approved.
- We have limited experience in launching and marketing approved products. If our products achieve regulatory approval and we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products we may not be able to generate substantial product sales revenue.
- Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services.
- Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used.
- If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our products or product candidates.
- Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators' ability to commercialize our current and any future approved products.
- We and/or our collaboration partners may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.
- Inadequate funding or government efficiency initiatives for the FDA and other government agencies could reduce agency staffing or hinder agency ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Changes in U.S. tax law may have a material adverse effect on our business, financial condition and results of operations, and changes in international trade relations may have a material adverse effect on the commercialization of some or all of our product candidates.
- Public health crises such as pandemics or similar outbreaks may have a significant negative impact on our clinical trials, nonclinical studies, development, manufacturing and commercialization of our product candidates and other aspects of our business, staff, and operations.
- Risks Related to Our Dependence on Third Parties
- Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.
- We contract with, and may in the future contract with, third parties for components of the manufacturing of our product candidates, including our antibody drug conjugate candidates. Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates.
- Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates.
- Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success.
- Commercialization collaborations will be important to our business. If we are unable to maintain commercialization collaborations, or if commercialization collaborations are not successful, our business could be adversely affected.
- If our information technology systems, or those third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.
- Risks Related to Our Intellectual Property
- Our success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties.
- If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed.
- We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.
- If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.
- If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.
- Risks Related to Legal Compliance Matters
- We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.
- If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
- We and our collaborators are subject to various healthcare laws, and our failure, or the failure of our collaborators, to comply with those laws could result in significant penalties and adversely affect our business, operations and financial condition.
- We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers; and other adverse business consequences.
- Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.
- Risks Related to Employee Matters and Human Capital Management
- Our future success depends on our ability to attract or retain key executives and to attract, retain and motivate qualified personnel.
- We may undertake internal restructuring activities, including associated workforce reductions, that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.
- We may need to grow or contract our organization, and we may experience difficulties in managing this growth or contraction, which could disrupt our operations.
- Risks Related to Our Common Stock
- We have been and may in the future be subject to securities litigation, which is expensive and could divert management attention and adversely impact our business.
- Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult.
Legal proceedings
Securities Litigation
In July 2024, a putative securities class action suit, entitled Crain v. MacroGenics, Inc. (Case No. 24-cv-02184), was filed in the U.S. District Court for the District of Maryland against the Company and Scott Koenig, M.D., Ph.D., the Company’s former President and Chief Executive Officer and a current member of the Company’s Board of Directors, alleging violations of securities laws during 2024. The suit asserted certain claims under Section 10 and Rule 10b-5 of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer. On December 20, 2024, the District Court issued an Order dismissing the case, without prejudice.
On December 9, 2024, a shareholder derivative suit, entitled Gregora v. Heiden et al. (Case No. 24-cv-03546), was filed in the U.S. District Court for the District of Maryland against certain of the Company’s officers and directors and naming the Company as a nominal defendant. The suit asserts certain claims under Section 10(b) and Rule 10b-5 of the Securities and Exchange Act of 1934 and for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the same facts as the Securities Class Action. On March 10, 2025, the plaintiff filed a notice of voluntary dismissal. On March 11, 2025, the Court entered an Order dismissing the case without prejudice.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARMACROGENICS INC filings on SEC EDGAR
- 2
- 3SEC EDGARMACROGENICS INC filings on SEC EDGAR
- 4
- 5SEC EDGARMACROGENICS INC 10-K for fiscal 2025
- 6SEC EDGARMACROGENICS INC 10-K for fiscal 2019
- 7SEC EDGARMACROGENICS INC 10-K for fiscal 2020
- 8SEC EDGARMACROGENICS INC 10-K for fiscal 2021
- 9SEC EDGARMACROGENICS INC 10-K for fiscal 2022
- 10SEC EDGARMACROGENICS INC 10-Q for fiscal 2026
- 11SEC EDGARMACROGENICS INC 10-Q for fiscal 2026
- 12SEC EDGARMACROGENICS INC 10-K for fiscal 2019
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARAtul Saran, Officer
- 21
- 22SEC EDGAREzio Bonvini, Senior V P, Research
- 23
- 24
- 25
- 26
- 27SEC EDGARMargaret Liu, Board member
- 28SEC EDGARMeenu Chhabra, Board member
- 29SEC EDGARWilliam K. Heiden, Board member
- 30SEC EDGARFederica F. O'Brien, Board member
- 31SEC EDGARKaren Jean Ferrante, Board member
- 32SEC EDGARScott Thomas Jackson, Board member
- 33SEC EDGARJay Philip Siegel, Board member
- 34SEC EDGARArnold L. Oronsky, Board member
- 35SEC EDGARDavid C. Stump, Board member
- 36SEC EDGAREdward Hurwitz, Board member
- 37SEC EDGAREran Nadav, Board member
- 38SEC EDGARKenneth Galbraith, Board member
- 39SEC EDGARPaulo F. Costa, Board member
- 40
- 41SEC EDGARAtul Saran, General counsel
- 42SEC EDGARFinancial statements and exhibits
- 43SEC EDGARResults of operations
- 44SEC EDGAROther events
- 45SEC EDGARExecutive or director change
- 46
- 47SEC EDGARShareholder vote
- 48SEC EDGARResults of operations
- 49
- 50
- 51SEC EDGAROther events
- 52SEC EDGARResults of operations
- 53SEC EDGAROther events
- 54NasdaqNasdaq calendar
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75SEC EDGARInvesco SC 13G/A on MACROGENICS INC
- 76